|
| 乳腺浸润性导管癌中EGFR蛋白的表达及分析 |
| Expression of EGFR protein in invasive ductal carcinoma and its analysis |
| |
| DOI： |
| 中文关键词: 乳腺浸润性导管癌 表皮生长因子受体 免疫组化 |
| 英文关键词: Invasive ductal carcinoma of breast Epidermal growth factor receptor Immunohistochemistry |
| 基金项目:基金项目：中国航天科工集团公司医疗卫生科研项目，项目编号：2018-LCYL-011 |
|
| 摘要点击次数: 572 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的：探讨乳腺浸润性导管癌中EGFR蛋白表达及其与临床病理的关系。方法：应用免疫组化MaxVinsonTM法检测乳腺浸润性导管癌和癌旁正常组织中EGFR蛋白的表达。结果：乳腺浸润性癌中EGFR的阳性表达率为65.0%，癌旁正常组织中的阳性表达率为20.0%，组间比较差异具有显著性（P＜0.05），阳性表达率与淋巴结转移有关（P＜0.01）。结论：EGFR可能与乳腺浸润性导管癌的发生、分化和预后有关，可以为靶向治疗提供参考依据。 |
| 英文摘要: |
| Objective: To investigate the expression of EGFR protein in invasive ductal carcinoma(IDC) and its relationship with clinicopathology. Methods: Immunohistochemical MaxVisionTM was used to detect the expression of EGFR protein both in IDC tissue and in normal adjacent issue. Results: The positive expression rate of EGFR in IDC tissue was 65.0%, and it was 20.0% in adjacent normal mucosa. The difference was statistically significant, with P<0.05. The positive expression rate was related to lymphatic metastasis, with P<0.01. Conclusion: EGFR may be related to the occurrence, differentiation and prognosis of IDC, providing a reference for the targeted therapy. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
